FORMULARY

3RD SHIFTING

DECEMBER 5, 2015
CAJIGAL
KRISCIA ANNE F.
 Thyroid Storm
Drug PROPYLTHIOURACIL

Category Antithyroid
MOA Inhibits T4 & T3 production by inhibiting
iodination of thyroglobulin.
Blocks T4 to T3 conversion by peripheral
tissues

Adverse GI disorders, stuma, exophthalmos,

Reaction leukopenia, thrombocytopenia,
,aggranulocytosis, thyrotoxic crisis after
discontinuing drug
Drug May interact with digoxin, theophylline, blood
Interaction thinners, or beta-blockers

Therapeutic Adult: 1-2 tabs 6hrs daily. Maintenance: 1-3

Dose tab/day
Children: 1-3 tabs/day. Maintenance: 1 tab
daily
Dosage Should be taken with food
Regimen
Drug Tablet
Preparation
 Thyroid Storm
Drug PROPRANOLOL (INDERAL)

Category Beta-Blockers
MOA A non cardioselective beta blocker that
completely blocks b1 and B2 receptors
resulting in decreased heart rate, myocardial
contractility, BP and myocardial oxygen
demand. It has membrane stabilizing
properties

Adverse Cold extremities, GI & sleep disturbances,

Reaction fatigue, lassitude. Deterioration in heart
failure, mood changes. Hypoglycemia,
paresthesia. Bradycardia, confusion, dizziness.

Drug Hypoglycemics, b-blockers w/ Class 1

Interaction antiarrhythmic agents, Ca-channel blockers,
dihydropyridines, alcohol, clonidine,
ergotamine.
Therapeutic 40 – 80 mg every 4 hours. PO, NG
Dose
Dosage Administer 1 tab BID
Regimen
Drug Tablet
Preparation
 Thyroid Storm
Drug LUGOL’S SOLUTION
Category Antithyroid, Antiseptic, Expectorant
MOA Blocks release of hormone from thyroid

Adverse Nausea, vomiting,

Reaction stomachache, diarrhea, metallic taste in
the mouth, fever, headache, runny
nose, sneezing, or acne may occur.
Drug ACE inhibitors, angiotensin receptor blockers,
Interaction certain "water pills”, drospirenone,
eplerenone, lithium, drugs that contain
potassium

Therapeutic 4 – 10 drops every 6 to 8 hours. PO, NG

Dose
Dosage 3 or 4 times daily (not to exceed 12 doses per
Regimen day)
Drug Solution
Preparation
 Obsessive – Compulsive Disorder
Drug Fluoxetine HCl (Motivest)

Category Anti-depressant
MOA Highly selective inhibitor of serotonin
reuptake. No affinity for adrenoceptors or
histamine, GABA-B, or muscarinic receptors

Adverse Asthenia, fever flu syndrome, headache,

Reaction vasodilation, anorexia, constipation, diarrhea,
dry mouth, dyspepsia, flatulence, nausea,
vomiting, weight loss, abnormal dreams and
thinking, anxiety, decreased libido, dizziness,
insomnia, nervousness, somnolence, tremor,
pharyngitis, sinusitis, sweating, pruritus.
Drug Management of generalized anxiety disorder,
Interaction obsessive compulsive disorder, panic
disorders, w/ or w/o agoraphobia, social
phobia & post traumatic stress disorder
Therapeutic Initial Dose: Adult >18 y/o 20mg/day as single
Dose dose in the morning or in 2 divided doses in
the morning and at noon.
Max: 80mg/day
Dosage with our without food
Regimen
Drug Capsule 20mg x 30’s (PHP 974.33)
Preparation
 Obsessive – Compulsive Disorder
Drug Clomipramine HCl (Anafranil)

Category Anti-depressant
MOA Potent inhibitor of serotonin reuptake in the
brain. Significant antagonism at cholinergic
and alpha1 receptors. Weak antagonism at
dopamine receptor. It has also antidepressant,
sedative, and anticholinergic effects
Adverse GI disturbance (dry mouth), constipation ,
Reaction nausea, dyspepsia, anorexia
Drug Alcohol, barbiturates, and other CNS
Interaction depressants, MAOIs.
Careful adjustments of dosage with
anticholinergic and sympathomimetric drugs.
Block pharmacologic effects of guanethidine,
clonidine, or similar agnts
Therapeutic Adults: Initially 25mg daily increased during
Dose the 1st 2 weeks up to 3mg/kg or 100mg then
up to 3mg/kg or 200mg.
Elderly: initially 10 mg daily
Dosage with or without food
Regimen
Drug Tab 25mg x 200’s (PHP 5,059)
Preparation
 Obsessive – Compulsive Disorder
Drug Venlafaxine (Effexor)

Category Anti-depressant
MOA Selectively inhibits the neuronal reuptake of
serotonin, norepinephrine, and to a lesser
extent dopamine. It has minimal affinity for
muscarinic, histamine, or alpha adrenergic
receptors.
Adverse Palpitations, tinnitus, vertigo, mydriasis,
Reaction nausea, dry mouth, constipation, diarrhea,
vomiting, fatigue, chills, asthenia, irritability,
wt. changes, increased BP & blood cholesterol,
decreased appetite, musculoskeletal stiffness,
headache, somnolence, tremor, delayed
ejaculation, hot flushes, erectile dysfunctiom,
decreased libido, anxiety, and attention
disturbance
Drug MAOIs, agents that may affect serotonergic
Interaction neurotransmitter systems (triptans, SSRIs,
SNRIs, lithium) ethanol, CYP3A4 inhibitors &
substates, increased risk of serotonin
syndrome w/ reversible MAOI
Therapeutic Extended release: 37.5-75 mg PO once daily
Dose initially; may be increased by 75 mg/day every
4-7 days; not to exceed 225 mg/day, Mild to
severe renal impairment: Reduce dosage by
 25-50%, Mild to moderate hepatic
impairment: Reduce dosage by 50%
Dosage Should be taken with food: swallow whole, do
Regimen not chew/crush/divide/dissolve
Drug Tab 50-75mg
Preparation
 Hemorrhagic Disease of the Newborn
Drug Vitamin K1 (Phytomenadione)
Category Hemostatics
MOA Promotes hepatic synthesis of clotting factors
II, VII,IX and X (exact mechanism is unknown).
Naturally occurring compound that is used to
prevent and treat hemorrhagic related to
vitamin K deficiency
Adverse Allergic reactions: anaphylactoid reaction,
Reaction pain, swelling, tenderness at injection site
Drug Coumarin and indanedion derivatives
Interaction
Therapeutic Neonatal: o.5 mg IM immediately after birth,
Dose 1-5 mg IM to mother 12-24 hrs before
delivery
Adult: 5-10 mg IM up tp 20mg
Dosage Dilute in preservative-free NS, D5W or D5NS
Regimen and infuse slowly; infusion rate not to exceed
1mg/min.
Drug IM Injection: Ampule 10mg/mL x 5’s (P544)
Preparation Pediatric injection (IV): Ampule 2mg/0.2mL
x5’s (P214)
 Hemorrhagic Disease of the Newborn
Drug Fresh Frozen Plasma
Category Blood Component
MOA Each unit provides all plasma proteins and
clotting factors to support dequate
hemostasis to treat or prevent bleeding or to
treat other protein deficiencies that cannot
be replaced with protein specific
concentrates.
Adverse Headache, paresthesia, nausea,
Reaction pruritus,urticaria, transfusion reactions,
anaphylaxis
Drug No data regarding drug interactions was
Interaction found.
Therapeutic 10-15mg/kg of body weight
Dose
Dosage 10 mg/kg of body weight
Regimen
Drug 1 unit
Preparation
 Hemorrhagic Disease of the Newborn
Drug Vitamin K1 (Phytomenadione)
Category Hemostatics
MOA Promotes hepatic synthesis of clotting factors
II, VII,IX and X (exact mechanism is unknown).
Adverse Shock-like reactions, phlebitis, dyspnea,
Reaction cyanosis, local pain or tenderness, erythema
at injection site.
Drug Anticoagulants
Interaction
Therapeutic A single 1 mg IM dose is recommended
Dose
Dosage 1 mg IM
Regimen
Drug IM Injection: Ampule 10mg/mL x 5’s (P544)
Preparation Pediatric injection (IV): Ampule 2mg/0.2mL
x5’s (P214)
 Acute Coronary Syndrome
Drug Aspirin
Category NSAIDs, anticoagulant, antiplatelets
MOA Relieves pain and reduces inflammation by
inhibition of peripheral prostaglandin
synthesis; decreases platelet aggregation by
preventing formation of Thromboxane A2.
Inhibits cyclooxygenase, which is responsible
for the synthesis of prostaglandin and
thromboxane.
Adverse Dyspepsia, GI bleeding, ulceration &
Reaction perforation, Reye’s syndrome,
hypersensitivity, thrombocytopenia
Drug Hypersensitivity, asthma, rhinitis, & nasal
Interaction polyps; history of active peptic ulcer.
Therapeutic 100 mg/tab ODAL; 300mg/tab
Dose
Dosage Should be taken with food: take immediately
Regimen after meals
Drug Tab 100mg
Preparation Tab 300 mg
 Acute Coronary Syndrome
Drug Clopidogrel bisulfate
Category Anticoagulants, antiplatelets & fibrinolytics
MOA Inhibition of platelet aggregation
Inhibits adenosine diphosphate (ADP) from
binding to its receptor sites on the platelets
and subsequent activation of glycoprotein GP
IIb/IIIa complex thus preventing fibrinogen
binding, platelet adhesion and aggregation
Adverse Abdominal pain, dyspepsia, gastritis, diarrhea,
Reaction constipation, GI hemorrhage, neutropenia,
rash, palpitations, syncope, asthenia,
neuralgia, paresthesia, vertigo
Drug Potentiates effects of aspirin on collagen
Interaction induced platelet aggregation. Risk of
increased occult GI blood loss with NSAIDs.
May interfere with metabolism of phenytoin,
tamoxifen, tolbutamide, warfarin, torsemide,
fluvastatin

Therapeutic 300 mg loading dose

Dose Followed by 75 mg once daily
Dosage May be taken with or without food
Regimen
Drug Film coated tab
Preparation
 Acute Glomerulonephritis
Drug Furosemide (Lasix)
Category diuretics
MOA Loop diuretic inhibits reabsorption of Na and
Cl mainly in the medullary portion of the
ascending loop of henle.
Excretion of K and ammonia is increased
while uric acid excretion is reduced. It
increases plasma renin activity, plasma
norepinephrine and plasma arginine
vasopressine concentration
Adverse Electrolyte disturbances (including
Reaction symptomatic), dehydration & hypovolemia
especially in the elderly, increased blood
creatinine & blood triglyceride,
hyponatremia, hypochloremia, hypokalemia,
increased blood cholesterol & blood uric acid
& attacks of gout, hypotension including
orthostatic hypotension, increased urine vol,
hepatic encephalopathy in patients w/
hepatocellular insufficiency.
Drug Chloral hydrate. Aminoglycosides & other
Interaction ototoxic drugs. Cisplatin. Sucralfate. Lithium
salts. ACE inhibitors or angiotensin II receptor
antagonist. Risperidone. NSAIDs including
aspirin. Phenytoin. Corticosteroids,
carbenoxolone, liquorice in large amounts &
 prolonged use of laxatives. Digitalis
preparations. Antihypertensives, diuretics or
other drugs w/ BP-lowering potential.
Probenecid, methotrexate & other drugs
which like furosemide undergo significant
renal tubular secretion. Antidiabetics & BP
increasing sympathomimetics (eg
epinephrine, norepinephrine), curare-type
muscle relaxants or theophylline, nephrotoxic
drugs, high doses of certain cephalosporins,
cyclosporine A.
Therapeutic Tab 40 mg x 150’s (P1, 975.31). Inj (amp) 20
Dose mg/2 mL x 5’s (P432.05).
Dosage Should be taken on an empty stomach:
Regimen swallow without chewing and with sufficient
amount of liquid
Drug Inj 20 mg/2ml
Preparation Tab 40 mg
 Acute Glomerulonephritis
Drug Spironolactone (Aldactone)
Category diuretics
MOA Acts on the distal portion of the renal tubules
as a competitive antagonist of aldosterone.
It increases the excretion of sodium chloride
and water while conserving potassium and
hydrogen ions
Adverse Benign breast neoplasm, leukopenia,
Reaction (including agranulocytosis),
thrombocytopenia, electrolyte disturbances,
hyperkalemia, changes in libido, confusion,
dizziness, GI disturbances, Stevens-Johnson
syndrome, toxic epidermal necrolysis, drug
rash with eosinophilia, alopecia,
hypertrichosis, pruritus, rash, urticarial, leg
cramps, acute renal failure, breast pain,
menstrual disorders, gynecomastia & malaise.
Drug Concomitant use of drug known to cause
Interaction hyperkalemia may result to severe
hyperkalemia.
Additive effect with other diuretics and
antihypertensives. May reduce vascular
responsiveness to norepinephrine. May
attenuate natriuretic efficacy of diuretics.
May enhance metabolism of antipyrine.
 May increase t1/2 of digoxin and interfere
with plasma digoxin concentration.
Therapeutic 100-200mg/day
Dose
Dosage Should be taken with food
Regimen
Drug tablet
Preparation
 Acute Glomerulonephritis
Drug Hydrochlorothiazide (Pharex Losartan
Potassium + Hydrochlorothiazide)
Category diuretics
MOA Inhibits the reabsorption of Na in the distal
tubules causing increase excretion of Na and
water including K and hydrogen Ions
Adverse Weakness, hypotension, pancreatiis,
Reaction jaundice, diarrhea, vomiting, sialadenitis,
cramping, constipation, gastric
agranulocytosis, leukopenia,
thrombocytopenia, anaphylactic reactions,
necrotizing angiitis, respiratory distress,
photosensitivity, fever, urticarial, rash,
purpura, electrolyte imbalance,
hyperglycemia, glycosuria, hyperuricemia,
muscle spasm, nervous system and renal
disorders, skin reactions, impotence.
Drug Hypersensitivity to losartan K &/or
Interaction hydrochlorothiazide or other sulfonamide-
derived drugs acidosis w/ concurrent use of
ammonium Cl or cholestyramine
Therapeutic Initially 1 tab once daily, may be increased
Dose to 2 tab once daily if BP remains
uncontrolled
Dosage Should be taken with food
Regimen
Drug FC Tab 100’s (P14/tab) (P1,400/box)
Preparation
 Testicular Teratoma
Drug Cisplatin
Category Platinum containing antineoplastic agent
MOA Forms intrastrand and interstrand DNA
cross-links; binding to nuclear and
cytoplasmicproteins
Modifies cell cycle by interfering with the
DNA structure and function. Effects are
most prominent during the S phase but cells
are killed at all stages. Cisplatin synergises
with other anti cancer drugs (fluorouracil)
Highly toxic
Adverse Nephrotoxicity, hepatotoxicity, &
Reaction neurotoxicity, myelosuppression, lhermitte’s
sign, dorsal column myelopathy, autonomic
neuropathy; loss of taste and seizures.
Muscle cramps, ototoxicity, leukopenia and
thrombocytopenia, serious bone marrow
depression
Drug Myelosuppresives or radiation,
Interaction anticonvulsants, antihypertensives
containing furosemide, hydralazine,
diazoxide, propranolol. Cephalosporins,
aminoglycosides, amphotericin B,
allopurinol, colchicine, probenicid,
sulfinpyrazone.
Therapeutic 20mg/m2 daily for 5 consecutive days at 3
Dose weeks interval for at least 4 cycles
Dosage Once every 3 week
Regimen
Drug IV
Preparation
 Testicular Teratoma
Drug Bleomycin
Category Antitumor antibiotics (G2–M phase)
MOA Oxygen free radicals bind to DNA causing
single- and double-strand DNA breaks
Adverse Allergic reactions, hypotension, Skin toxicity,
Reaction pulmonary fibrosis, mucositis, alopecia
Drug
Interaction
Therapeutic 10-20 u/m²
Dose
Dosage Weekly or BID weekly
Regimen
Drug IV/IM
Preparation
 Testicular Teratoma
Drug Etoposide
Category Epipodophyllotoxin (topoisomerase II
inhibitor) (G1–S phase)
MOA Derivative of podophyllotoxin that inhibits
DNA synthesis resulting in the arrest of the
cell cycle. At low doses, it inhibits cells from
entering cell cycle and at high doses, cell
entering mitosis are lysed.
Adverse Granulocytopenia, thrombocytopenia, Gi
Reaction effects, mucositis, anaphylactic like
symptoms, alopecia
Drug cisplatin
Interaction
Therapeutic 50-100 mg/m2/day for 5 days,
Dose
Dosage For 5 days, repeat 3-4 weekly
Regimen
Drug 100 mg inj.
Preparation
 Endometriosis
Drug Danazol
Category Androgens and related synthetic drugs
MOA Suppresses the pituitary ovarian axis by
reducing the release of follicle stimulating
hormone and lutenizing hormone. This
causes the regression and trophy of
endometrial tissue, decreases growth rate
of abnormal breast tissue and reduces
attack in hereditary angioedema.
Adverse Acne, weight gain, increase appetitie,
Reaction seborrhea, hirsutism, hair loss, voice
change, disturbance of menstrual cycle,
intermenstrual spotting, amenorrhea,
flushing, vaginal dryness/ irritation, changes
in libido. Rashes which may be
maculopapular, petechial or purpuric and
accompanied by fever.
Drug Anticonvulsives (carbamazepine)
Interaction antidiabetics as danazol can cause insulin
resistance. May potentiate effect of
warfarin. Diminish effectiveness of
antihypertensives. Cyclosporine and
tacrolimus. Increased risk of myopathy and
rhabdomyolysis with statins.
Therapeutic 400 mg daily for 6-9 months
Dose
Dosage Initiate during menstruation. Course of
Regimen continuous treatment lasts for 3-6 months
Drug Cap 200 mg
Preparation
 Endometriosis
Drug Goserelin
Category Trophic hormone
MOA Goserelin is a synthetic decapeptide analogue
of LHRH. It acts as a potent inhibitor of
pituitary gonadotropin secretion when
administered in the biodegradable
formulation. It causes an increase in the serum
levels of FSH and LH but chronicadministration
will lead to sustained suppression of the
pituitary release causing regression of the sex
organs
Adverse Decreased libido, hot flushes, hyperhidrosis
Reaction ,paresthesia, abnormal BP, rash , decreased
bone density, weight gain, injection site
reaction
Drug Pregnancy
Interaction
Therapeutic 1 depot inj SC into the anterior abdominal
Dose wall every 28 days
Dosage
Regimen
Drug Inj 3.6 mg
Preparation In 10.8 mg
 Endometriosis
Drug Leuprolin Acetate
Category Cancer hormone therapy
MOA Gonadotropin releasing hormone analogue.
Following initial stimulation of
gonadotrophins, continuous admin of
leuprorelin leads to the down regulation of
GnRH receptors and subsequent reduces
pituitary gonadotrophin secretion. Reduced
gonadotrophin levels leads to inhibition of sex
hormone production.
Adverse Interstitial pneumonia , anaphylaxis symptoms
Reaction
Drug Hypersensitivity to synthetic gonadotropin or
Interaction LH-releasing hormone derivatives.
Undiagnosed abdominal vaginal bleeding
Therapeutic 3.75mg inj during first 5 days of mensturation
Dose
Dosage Renewed every 4 weeks. Not >6 months
Regimen duration
Drug Inj for soln 3.75 mg
Preparation
 Hyperprolactinemia
Drug Bromocriptine (Parlodel)
Category Dopamine receptor agonist, Anti-
parkinsonian and Semisynthetic ergot
derivative
MOA Acts directly on post synaptic dopamine
receptors of the prolactin secreting cells in
the anterior pituitary, mimicking the effects
of prolactin inhibitory factor, inhibiting the
synthesis and release of prolactin.
Adverse Dizziness, fatigue, light-headedness, nasal
Reaction congestion, drowsiness, headache, CSF
rhinorrhea in patients who have sphenoidal
surgery, pituitary radiation.
Drug Erythromycin: Increased serum levels and
Interaction increased toxic effects
Phenothiazines: Decrease effectiveness for
treatment of prolactinomas
Sympathomimetics: Increased in the side
effects of bromocriptine
Therapeutic Therapy is initiated by administering a low
Dose bromocriptine dose (0.625–1.25 mg) at
bedtime with a snack, followed by gradually
increasing the dose. Most patients are
controlled with 2.5mg/tab TID.
Dosage 2.5mg
Regimen
Drug Tablet- 2.5mg Capsule- 5mg
Preparation
 Hyperprolactinemia
Drug Cabergoline (Dostinex)
Category Dopamine receptor agonist and semisynthetic
ergot derivative
MOA The secretion of prolactin by the anterior
pituitary is mainly under hypothalamic
inhibitory control, likely exerted through
release of dopamine by tuberoinfundibular
neurons. Cabergoline is a long-acting
dopamine receptor agonist with a high affinity
for D2 receptors.
Adverse CNS: Headache, dizziness, vertigo and
Reaction paresthesia
CV: hypotension, syncope and palpitations
GI: dry mouth, flatulence, diarrhea and
anorexia.
Drug Phenothiazines: Decrease effectiveness for
Interaction treatment of prolactinomas
Sympathomimetics: Increased in the side
effects of Cabergoline
Therapeutic Initial: 0.25mg twice per week PO
Dose May increase by 0.25 mg q 4Weeks (or longer)
up to 1 mg 2 times per week
Dosage 0.25mg
Regimen
Drug Tablet- 0.5mg
Preparation
 Conn’s Disease
Drug Nifedipine
Category Ca channel blocker
MOA By inhibiting the intracellular calcium flux in
the adrenocortical cells, the dihydropyridine
calcium channel blockers reduce the
production of aldosterone in response to a
variety of stimulants, including potassium,
corticotropin, and angiotensin-II
Adverse Dizziness, flushing, headache, hypotension,
Reaction peripheral edema. Rarely, abnormalities in
liver function. Chest pain.
Drug Effects enhanced by antihypertensive agents,
Interaction cimetidine & β-receptor blockers. Digoxin,
quinidine (monitor plasma level).
Therapeutic 20mg BID.
Dose
Dosage 1 tab BID. May increase slowly to 2 tab BID.
Regimen
Drug Capsule: 5-10mg
Preparation Tablet: 20mg
 Conn’s Disease
Drug Prednisone
Category Glucocorticoids
MOA Prednisone is a synthetic steroid which is
easily absorbed from the gastrointestinal tract.
In the liver, it is immediately and almost
completely converted into the active
glucocorticoid, prednisolone, which has 4
times the anti-inflammatory potency and 0.8
times the salt-retaining potency of the natural
adrenocortical hormone, hydrocortisone
Adverse Cushing-like syndrome, hirsutism, menstrual
Reaction irregularities, premature epiphyseal closure,
secondary adrenocortical and pituitary
unresponsiveness, decreased glucose
tolerance, negative nitrogen and calcium
balance
Drug Amphotericin B; cyclosporine; digoxin,
Interaction digitalis; St. John's wort; an antibiotic such as
clarithromycin or telithromycin; antifungal
medication such as itraconazole,
ketoconazole, posaconazole, voriconazole;
birth control pills and other hormones; a blood
thinner such as warfarin, Coumadin
Therapeutic 5mg daily in divided doses
Dose
Dosage 5-25mg in divided doses
Regimen
Drug Tablet: 5mg
Preparation
 Conn’s Disease
Drug Spironolactone
Category Mineralocorticoid antagonists
MOA Spironolactone is a specific pharmacologic
antagonist of aldosterone, acting primarily
through competitive binding of receptors at
the aldosterone-dependent sodium-potassium
exchange site in the distal convoluted renal
tubule. It causes increased amounts of sodium
and water to be excreted, while potassium is
retained.
Adverse Benign breast neoplasm, leukopenia,
Reaction thrombocytopenia, hyperkalemia, confusion,
dizziness, nausea, GI disturbances, abnormal
hepatic function, Stevens-Johnson syndrome,
leg cramps, acute renal failure, menstrual
disorders, breast pain.
Drug Concomitant use of drugs known to cause
Interaction hyperkalemia may result in severe
hyperkalemia. Additive effect w/ other
diuretics & antihypertensives. Norepinephrine.
Therapeutic 100mg daily
Dose
Dosage 100-400mg daily for 4 days
Regimen
Drug Tablet: 25, 50, 100mg
Preparation
 Post-Partum Hemorrhage
Drug OXYTOCIN
Category OXYTOCIC AGENT
MOA Uterine motility depends on the formation of
the contractile protein actomyosin under the
influence of the Ca2+-dependent
phosphorylating enzyme myosin light-chain
kinase. Oxytocin promotes contractions by
increasing the intracellular Ca2+, which in turn
activates myosin's light chain kinase.
Adverse Sinus bradycardia, tachycardia, Neonatal
Reaction seizure, Neonatal jaundice, fetal hypoxia
Drug Cervidil, Dinoprostone topical, prepidil, Prostin
Interaction E2
Therapeutic For early onset PPH: 10 unit IM after delivery of
Dose placenta
For late onset PPH: Add 10-40 units (not to
exceed 40 units) to 1L of non-hydrating IV
solution and infuse at necessary rate to control
uterine atony

Dosage
Regimen
Drug Duration: 2-3 hr (IM); 1 hr (IV)
Preparation
 Post-Partum Hemorrhage
Drug ERGONOVINE MALEATE
Category OXYTOCIC AGENT
MOA Powerful stimulant effect on the uterus
Most closely associated with agonist or partial
agonist effects at 5-HT2 receptors
Adverse Diarrhea, nausea, vomiting
Reaction
Drug
Interaction
Therapeutic Initial dose of 100 or 125 mcg intravenously or
Dose intramyometrially or
200 or 250 mcg intramuscularly
The maximum total dose is 1.25 mg
Dosage IV or IM
Regimen
Drug
Preparation
 Post-Partum Hemorrhage
Drug CARBOPROST TROMETHAMINE
Category PROSTAGLANDINE; 15-methyl-PGF2α
MOA Inhibits or stimulates smooth muscle
contraction, which results in expulsion of the
products of conception and is used to induce
abortion between 13-20 weeks of pregnancy;
inhibits release of norepinephrine or
modulates its effects at neuroeffector sites
Adverse Asthma, shock, vomiting, diarrhea
Reaction
Drug Oxytocin
Interaction
Therapeutic It is administered as a single 250-mcg
Dose intramuscular injection, repeated if
necessary.

Dosage IM
Regimen
Drug
Preparation
 Myxedema Coma
Drug Levothyroxine
Category
MOA Levothyroxine acts like the endogenous
thyroid hormone thyroxine (T4, a tetra-
iodinated tyrosine derivative). In the liver and
kidney, T4 is converted to T3, the active
metabolite. In order to increase solubility,
the thyroid hormones attach to thyroid
hormone binding proteins, thyroxin-binding
globulin, and thyroxin-binding prealbumin
(transthyretin). Transport and binding to
thyroid hormone receptors in the cytoplasm
and nucleus then takes place. Thus by acting
as a replacement for natural thyroxine,
symptoms of thyroxine deficiency are
relieved.
Adverse Symptoms of thyrotoxicosis include weight
Reaction loss, increased appetite, palpitations,
nervousness, diarrhea, abdominal cramps,
sweating, tachycardia, increased pulse and
blood pressure, cardiac arrhythmias, tremors,
insomnia, heat intolerance, fever, and
menstrual irregularities.
Drug Amifampridine
Interaction
Therapeutic The usual dose is 1.7 microgram (mcg) per
Dose kilogram (kg) per day but may be less in older
adults.
Dosage
Regimen
Drug Tablet
Preparation
 Myxedema Coma
Drug Liothryronine
Category
MOA The hormones, T4 and T3, are tyrosine-based
hormones produced by the thyroid gland.
Iodine is an important component in their
synthesis. The major form of thyroid
hormone in the blood is thyroxine (T4). This
is converted to the more active liothyronine
form by deiodinases in peripheral tissues.
Liothyronine acts on the body to increase
the basal metabolic rate, affect protein
synthesis and increase the body's sensitivity
to catecholamines (such as adrenaline). The
thyroid hormones are essential to proper
development and differentiation of all cells
of the human body. To various extents
T4 and T3 regulate protein, fat and
carbohydrate metabolism. Their most
pronounced effect is on how human cells
use energetic compounds.
Adverse Tachycardia, Po2 Increased, Pharmaceutical
Reaction Product Complaint, Petit Mal Epilepsy, Pco2
Increased
Drug Acenocoumarol, Anisindione, Dicumarol,
Interaction Kelp, Phenindione, Phenprocoumon and
Warfarin
Therapeutic First, 25 micrograms (mcg) once a day.
Dose Doses may be increased by up to 25 mcg
every 1 or 2 weeks. However, the dose
usually is not more than 75 mcg once a day
Dosage
Regimen
Drug Tablet
Preparation
Myxedema Coma
Drug Liothrix
Category
MOA The hormones, T4 and T3, are tyrosine-based
hormones produced by the thyroid gland.
Iodine is an important component in their
synthesis. The major secreted form of thyroid
hormone is T4. T4 is converted T3, the more
active thyroid hormone, by deiodinases in
peripheral tissues. T3 acts in the body to
increase basal metabolic rate, alter protein
synthesis and increase the body's sensitivity
to catecholamines (such as adrenaline).
Thyroid hormones are essential for proper
development and differentiation of all cells of
the human body. T4 and T3 regulate protein,
fat and carbohydrate metabolism to varying
extents.
Adverse Hypermetabolic state indistinguishable from
Reaction thyrotoxicosis of endogenous origin.
Symptoms of thyrotoxicosis include weight
loss, increased appetite, palpitations,
nervousness, diarrhea, abdominal cramps,
sweating, tachycardia, increased pulse and
blood pressure, cardiac arrhythmias, tremors,
insomnia, heat intolerance, fever, and
menstrual irregularities
Drug Amifampridine
Interaction
Therapeutic 1 tablet of liotrix containing 6.25 microgram
Dose (mcg) of liothyronine and 25 mcg of
levothyroxine once a day
Dosage
Regimen
Drug Tablet
Preparation
Delayed Puberty
Drug Somatropin
Category
MOA hGH binds to the human growth hormone
receptor. Upon binding, hGH causes
dimerization of GHR, activation of the GHR-
associated JAK2 tyrosine kinase, and tyrosyl
phosphorylation of both JAK2 and GHR. These
events recruit and/or activate a variety of
signaling molecules, including MAP kinases,
insulin receptor substrates,
phosphatidylinositol 3' phosphate kinase,
diacylglycerol, protein kinase C, intracellular
calcium, and Stat transcription factors. These
signaling molecules contribute to the GH-
induced changes in enzymatic activity,
transport function, and gene expression that
ultimately culminate in changes in growth and
metabolism. .
Adverse Headache, muscle pain, joint stiffness & pain,
Reaction swollen hands and feet due to fluid retention.
Drug Bexarotene, Levomethadyl acetate
Interaction
Therapeutic SC injection in the evening. Adult Replacement
Dose therapy, start treatment w/ 0.1-0.3 mg/day,
increase gradually at monthly intervals
Dosage
Regimen
Drug Injection 5mg/1.5 mL x 1’s (7,700 pesos)
Preparation
Delayed Puberty
Drug Hydrocortisone Na succinate
Category
MOA Hydrocortisone binds to the cytosolic
glucocorticoid receptor. After binding the
receptor the newly formed receptor-ligand
complex translocates itself into the cell
nucleus, where it binds to many
glucocorticoid response elements (GRE) in
the promoter region of the target genes.
Adverse Na & fluid retention, K loss, hypokalemic
Reaction alkalosis
Drug Bupropion, Ciprofloxacin, Etanercept
Interaction
Therapeutic IV/slow injection or infusion. Usual dose:
Dose 100-500 mg repeated tid or qid
Dosage
Regimen
Drug (vial) 100mg x 1’s (172 pesos)
Preparation
Delayed Puberty
Drug Testosterone Undecanoate (nebido)
Category
MOA Is an ester of the androgen, testosterone.
Endogenous androgens, including
testosterone and dihydrotestosterone (DHT)
are responsible for the normal growth and
development of the male sex organs and for
maintenance of secondary sex characteristics.
Male hypogonadism is a clinical syndrome
resulting from insufficient secretion of
testosterone. It has two main etiologies.
Primary hypogonadism is caused by defects
of the gonads, whereas secondary
hypogonadism is the failure of the
hypothalamus (or pituitary) to produce
sufficient gonadotropins (FSH, LH).
Adverse Itching, acne, nausea, changes in liver
Reaction function tests/cholesterol levels, depression,
nervousness, mood disturbances, myalgia,
edema
Drug Warfarin, Insulin
Interaction
Therapeutic Initially 120-160 mg daily for 2 – 3 week.
Dose Maintenance 40 – 120 mg/daily
Dosage
Regimen
Drug inj 250 mg/mL x 4 mL ( 9,644.25 pesos)
Preparation
 Gilles de la Tourette Syndrome (Tics)
Drug CLONIDINE
Category alpha2A-adrenergic receptor agonists
MOA Postsynaptic alph2-agonist stimulation may
regulate subcortical activity in the prefrontal
cortex, which may regulate area of the brain
responsible for attentions, emotions, and
behaviors and causes reduced hyperactivity,
distractibility, and impulsiveness
Adverse Skin reactions; patch, dry mouth,
Reaction somnolence, headache, fatigue, drowsiness,
dizziness, hypotension, epidural postural
hypotension, anxiety
Drug Aripiprazole, methylphenidate,
Interaction dexmethylphenidate, risperidone,
lisdexamfetamine
Therapeutic 0.2-0.9 mg/d
Dose
Dosage 0.0025-0.015 mg/kg/day PO for 6 weeks to 3
Regimen months
Drug tablet
Preparation
 Gilles de la Tourette Syndrome (Tics)
Drug GUANFACINE
Category alpha2A-adrenergic receptor agonists
MOA Stimulation of alpha-2 adrenergic receptors in
the prefrontal cortex results in enhanced
executive functioning, increased attentiveness,
and improvements in working memory. In
patients with ADHD, improved
neurotransmission in this region increases the
ability to control or inhibit inappropriate
behaviors and increase focus.
Adverse sedation
Reaction
Drug Amisulpride, amitriptyline, amoxapine,
Interaction atenolol, betaxolol, bisoprolol, clomipramine,
desipramine, diltiazem
Therapeutic 0.05-0.12 mg/kg/day
Dose
Dosage 6-18 years: Intuniv 1 mg/day PO initially; may
Regimen adjust dose using increasing increments (not
exceeding 1 mg/wk) Take once daily, either in
the morning or evening, at approximately the
same time each day
Drug tablet
Preparation
 Gilles de la Tourette Syndrome (Tics)
Drug HALOPERIDOL
Category Antipsychotic
MOA Antagonizes dopamine D1 and D2 receptors in
brain; depresses reticular activating system
and inhibits release of hypothalamic and
hypophyseal hormones
Adverse Extrapyramidal symptoms, tardive dyskinesia,
Reaction neuroleptic malignant syndrome,
hypersensitivity reactions
Drug CNS depressant drugs, alcohol, hypnotics,
Interaction sedatives or strong analgesics
Therapeutic 0.05-0.075 mg/kg
Dose
Dosage 3-12 years: 0.5 mg/day PO initially; dose
Regimen increased by 0.5 mg every 5-7 days until
therapeutic effect achieved, then reduced to
lowest effective maintenance level of 0.05-
0.075 mg/kg/day PO divided q8-12hr
Drug Tablet, injection
Preparation
 THREATENED ABORTION FORMULARY
Drug Dydrogesterone (Duphaston)
Category Oestrogens, Progesterones & Related
Synthetic Drugs
MOA Dydrogesterone is an orally active
progestogen which produces a complete
secretory endometrium in an estrogen-
primed uterus thereby providing protection
against the increased risk for endometrium
hyperplasia and/or carcinogenesis induced by
estrogens. It is indicated in all cases of
endogenous progesterone deficiency.
Dydrogesterone has no estrogenic,
androgenic, thermogenic, anabolic and
corticoid activity.
Adverse Migraines/headache, nausea, menstrual
Reaction disorders and breast pain.
Drug Increased metabolism with anti-convulsants,
Interaction anti-infectives and herbal preparations
containing St. John’s wort, valerian root, and
sage or Gingko biloba. Ritonavir and
nelfinavir.
Therapeutic An initial dose of up to 40 mg may be given
Dose followed by 20 or 30 mg/day until symptoms
remit.
Dosage
Regimen
Drug Tablet
Preparation
 THREATENED ABORTION FORMULARY
Drug Progesterone (Crinone)
Category Oestrogens, Progesterones & Related
Synthetic Drugs
MOA Those of the naturally occurring progesterone
with induction of a full secretory
endometrium. The progesterone vaginal gel is
based on a polycarbophil delivery system
which attaches to the vaginal mucosa and
provides a prolonged release of progesterone
for at least 3 days.
Adverse Abdominal pain, perineal pain, headache,
Reaction constipation, diarrhea, nausea, joint pain,
depression, decreased libido, nervousness,
somnolence, breast tenderness/pain,
dyspaerunia, nocturia; allergy, bloating,
cramps, fatigue, pain, dizziness, vomiting,
genital moniliasis/pruritus, aggressive
reactions, forgetfulness, vaginal dryness,
cystitis, urinary tract infection, vaginal
discharge
Drug Increased metabolism with anti-convulsants,
Interaction anti-infectives and herbal preparations
containing St. John’s wort, valerian root, and
sage or Gingko biloba. Ritonavir and nelfinavir
Therapeutic Intravaginal. 1 application (1.125 g) every day,
Dose starting after documented ovulation or
arbitrarily on the 18th-21st day of the cycle.
When used during in vitro fertilization: Daily
application of Crinone should be continued for
30 days if there is laboratory evidence of
pregnancy.
Dosage
Regimen
Drug Gel 8%
Preparation
 THREATENED ABORTION FORMULARY
Drug Hydroxyprogesterone (Makena)
Category Oestrogens, Progesterones & Related
Synthetic Drugs
MOA Form of progestin, a man made form of a
female hormone called progesterone.
Makena is used to lower the risk of
premature birth in a woman who has already
had one premature baby. This medication will
not stop premature labor that has already
begun. Makena is not for use in women who
have had more than one pregnancy.
Adverse Body as a whole: Local injection site reactions
Reaction (including erythema, urticaria, rash, irritation,
hypersensitivity, warmth); fatigue; fever; hot
flashes/flushes; Digestive
disorders: Vomiting; Infections: Urinary tract
infection; Nervous system
disorders: Headache, dizziness; Pregnancy,
puerperium and perinatal
conditions: Cervicalin competence,
premature rupture of membranes
Drug Acetaminophen, Alosetron, Betaxolol,
Interaction Propranolol, Cyclophosphamide, Efavirenz,
Methadone, Nicotine, anti-depressants,
asthma medication, muscle relaxants,
psychiatric drugs
Therapeutic Administer intramuscularly at a dose of 250
Dose mg (1 mL) once weekly (every 7 days) by a
healthcare provider. Begin treatment
between 16 weeks, 0 days and 20 weeks, 6
days of gestation. Continue administration
once weekly until week 37 (through 36
weeks, 6 days) of gestation or delivery,
whichever occurs first
Dosage
Regimen
Drug Injection
Preparation
 Idiopathic thrombocytopenic purpura
Drug Prednisone
Category Corticosteroids
MOA Immediately and completely converted to
active prednisolone in the liver.
It has anti-allergic, antitoxic, antipyretic and
immunosupressive properties by inhibiting
prostaglandin synthesis.
Half-life is 12-36hrs
Adverse Gastric and duodenal ulceration, possible
Reaction perforation and hemorrhage
Drug Diuretics, cardiac glycosides and antidiabetics
Interaction
Therapeutic 1mg/kg po
Dose
Dosage
Regimen
Drug 5mg x 500’s (P1,883.63)
Preparation
 Idiopathic thrombocytopenic purpura
Drug Rituximab
Category Anti-neoplasia
MOA Depletion of B lymphocytes reduces
inflammation by decreasing the
presentation of antigens to T lymphocytes
and inhibiting cytokines.
Adverse Infusion related reactions, angioedema,
Reaction infections, blood dyscrasias, GI upset, fever,
chills and weight loss
Drug Vaccines, antihypertensive drugs
Interaction
Therapeutic Initiate infusion at a rate of 100mg/hr and
Dose increase infusion rate by 100mg/hr
increments at 30 minutes, maximum dose
of 400mg/hr
Dosage
Regimen
Drug Infusion (Vial) 10mg/ml x 10ml 2’s (P36,422)
Preparation
 Idiopathic thrombocytopenic purpura
Drug Methylprednisolone
Category
MOA It inhibits migration of leukocytes and
macrophages to the site of inflammation.
Adverse Endocrine abnormalities, postmenopausal
Reaction bleeding, growth suppression in children and
cardiac disorders.
Drug Antibiotic, drugs for TB like Rifampicin,
Interaction Anticonvulsants, Anticoagulants
Therapeutic 1g IV once/day for 3 days
Dose
Dosage
Regimen
Drug 1g/16ml x 1’s (P5,030.97)
Preparation
 Aplastic Anemia
Drug Antithymocyte globulin, equine (Atgam)
Category Immunosuppressive Drugs
MOA The mechanism of ATGAM therapy for
aplastic anemia is attributed to its
immunosuppressive actions. In addition,
ATGAM directly stimulates the growth of
hematopoietic stem cells and release of
hematopoietic growth factors such as
interleukin-3 and granulocyte/macrophage
colony stimulating factor.
Adverse The most common (>10%) adverse reactions
Reaction are pyrexia, chills, rash, thrombocytopenia,
leukopenia and arthralgia
Drug Corticosteroids
Interaction
Therapeutic
Dose
Dosage 10-20 mg/kg/day for 8-14 days
Regimen
Drug IV
Preparation
 Aplastic Anemia
Drug Leukine (Sargramostim)
Category yte-macrophage colony-stimulating factor
(rHuGM-CSF)
MOA Increase concentration of hematopoietic
stem cells in the peripheral blood.
Stimulates the formation of erythrocytes and
platelets, they are sometimes combined with
other growth factors for treatment of
pancytopenia.
Adverse Abdominal pain Diarrhea
Reaction Asthenia
Malaise
Rash
Chest pain
Peripheral edema
Drug Busulfan, Bleomycin, Fluorouracil
Interaction
Therapeutic
Dose
Dosage 250 mcg/m2/day
Regimen
Drug IV
Preparation
 Aplastic Anemia
Drug Anadrol (Oxymetholone)
Category Anabolic steroids
MOA Oxymetholone has anabolic and androgenic
properties. It is used in the treatment of
aplastic anemia to enhance the production
and urinary excretion of erythropoietin due to
bone marrow failure and can stimulate
erythropoiesis in anemia due to deficient red
cell production
Adverse Males:
Reaction Pre-pubertal phallic enlargement with
increased frequency of erection, impotency,
priapism, bladder irritability

Pediatrics:
Premature closure of epiphyses
Drug Warfarin, Anisinidione, Dicumarol
Interaction
Therapeutic
Dose
Dosage 1-5 mg/kg body weight per day
Regimen
Drug Tablets
Preparation
 Chronic Renal Failure
Drug Thiazide
Category Diuretics
MOA Blocks Na/Cl transporter in renal distal
convoluted tubule
Adverse Headache, dizziness, rhinitis, cough, upper
Reaction respiratory tract infection, fatigue, nausea,
vomiting, and dyspepsia, myalgia
Drug May reduce the absorption of tetracyclines
Interaction
Therapeutic 25, 50 mg daily
Dose
Dosage 25 mg once daily
Regimen
Drug Tablet
Preparation
 Chronic Renal Failure
Drug Losartan
Category Angiotensin Receptor Blockers (ARBs)
MOA Blocks AT1 angiotensin receptors
Adverse Viral infections, postural dizziness, orthostatic
Reaction hypotension, neutropenia, upper respiratory
infection, pharyngitis, sinusitis, hyperkalemia
Drug Concomitant use of K-sparing diuretics, K
Interaction supplements. Triple combination with ACE
inhibitors and beta-blockers not
recommended
Therapeutic 25, 50, 100 mg tablets daily
Dose
Dosage 50 mg once daily
Regimen
Drug Tablet
Preparation
 Chronic Renal Failure
Drug Lisinopril
Category Angiotensin-Converting Enzyme (ACE)
Inhibitors
MOA Inhibit angiotensin-converting enzyme
Adverse Taste disturbance, skin reactions,
Reaction hypotension, dizziness, fatigue, headache, GI
disturbances, persistent dry cough, upper
respiratory tract symptoms, skin rashes
example, erythema multiforme, toxic
epidermal necrolysis
Drug Diuretics, K-sparing diuretics, K supplements,
Interaction K-containing salt substitutes, indomethacin,
lithium, insulin and oral antidiabetic drugs
Therapeutic 2.5, 5, 10, 20, 40, 80 mg tablets daily
Dose
Dosage 10 mg once daily
Regimen
Drug Tablet
Preparation
 Growth Hormone Deficiency
Drug Somatropin
Category Growth Hormone
MOA Recombinant form of human GH acts through
GH receptors to increase production of
insulin-like growth factor-1 (IGF-1)
Adverse Scoliosis, edema, gynecomastia, intracranial
Reaction HPN, myalgia, arthralgia, carpal tunnel
syndrome, increased CYP450 activity.
Drug Bexarotene, Levomethadyl acetate
Interaction
Therapeutic SC injection 3-7x/wk
Dose
Dosage
Regimen
Drug Injection
Preparation
 Growth Hormone Deficiency
Drug Mecasermin (Somatomedin C)
Category IGF-1 Agonist
MOA Recombinant form of IGF-1 that stimulates
IGF-1 receptors
Adverse Hypoglycemia, intracranial HPN, increased
Reaction liver enzymes.
Drug Glucotrol, Insulin, Metformin
Interaction
Therapeutic SC injection 2x/d also contains recombinant
Dose human IGF-binding protein-3, which prolongs
the half-life of the rIGF-1
Dosage
Regimen
Drug Injection
Preparation
 Schizophrenia
Drug HALOPERIDOL
Category Butyrophenon derivative antipsychotic
MOA It is postulated that the behavioral effect of
neuroleptic drugs is mediated through the
inhibitory pathways of the extrapyramidal
midbrain system.
It is thought that haloperidol, a
butyprophenone, may act by mimicking
gamma aminobutyric acid (GABA) and
opposing the action of glutamic acid,
particularly in specific areas of the
extrapyramidal system.
The antipsychotic action of haloperidol could
be correlated with surface tension lowering
properties and the consequent ability to form
a monomolecular film on certain cell
membranes.
Adverse Tardive dyskinesia, neuroleptic malignant
Reaction syndrome, extrapyramidal symptoms; tremor,
parkinsonism, somnolence, masked facies,
akathisia, sedation; dry mouth, constipation,
salivary hypersecretion; muscle rigidity; sexual
dysfunction; inj site reaction; increased wt.
Drug Drugs known to prolong QT interval & cause
Interaction electrolyte imbalance. Mild to moderate
 increased conc w/ substrates or inhibitors of
CYP3A4 or CYP2D6 isozymes eg itraconazole,
nefazodone, buspirone, venlafaxine,
alprazolam, fluvoxamine, quinidine, fluoxetine,
sertraline, chlorpromazine & promethazine.
Increase QTc in combination w/ metabolic
inhibitors ketoconazole & paroxetine. Reduced
plasma levels when prolonged treatment w/
enzyme-inducing drugs eg carbamazepine,
phenobarb, rifampicin is added to therapy.
Therapeutic
Dose
Dosage Tab Adult Psychoses & associated behavioral
Regimen disorders 0.5-5 mg bid-tid.
Severe psychoses Up to 100 mg/day. Gradually
reduce dose to the lowest effective
maintenance dose when max improvement is
reached.
Childn 3-12 yr Initially 0.5 mg/day, may be
increased by 0.5 mg increments at 5-7 day
intervals. Max: 0.15 mg/kg/day.
Psychotic disorders 0.05-0.15 mg/kg/day in 2-3
divided doses
Drug Tab 5 mg x 50's, (P1,436/ P28.72 per tab)
Preparation 20 mg x 50's, (P2,922.28/ P59.85 per tab)
Inj 5 mg/mL x 5's. (P1,122.91/ P224.58 per
vial)
 Schizophrenia
Drug DIVALPROEX SODIUM (Depakote)
Category anticonvulsant/ mood stabilizer
MOA Divalproex is converted to valproic acid in the
stomach. Scientists do not know the
mechanism of action of valproic acid. The
most popular theory is that valproic acid
exerts its effects by increasing the
concentration of gamma-aminobutyric acid
(GABA) in the brain.

Adverse Intolerance. Headache, asthenia, fever.

Reaction Nausea, vomiting, abdominal pain, diarrhea,
anorexia, dyspepsia, constipation.
Somnolence, tremor, dizziness, diplopia,
amblyopia/blurred vision, ataxia, nystagmus,
emotional lability, abnormal thinking,
amnesia, insomnia, nervousness, depression.
Drug Decreased protein-binding & inhibits the
Interaction metabolism of valproate w/ aspirin. Reduced
serum conc of ertapenem, imipinem &
meropenem. Increased mean peak conc w/
felbamate. Increased clearance w/ rifampin.
Increased trough plasma levels w/
chlorpromazine.
Therapeutic
Dose
Dosage Mania 25 mg/kg/day once daily. Increase dose
Regimen as rapidly as possible to achieve the lowest
therapeutic dose which produces the desired
clinical effect or the desired range of plasma
conc.
Placebo-controlled clinical trial of acute mania
or mixed type patients Dose to a clinical
response w/ a trough plasma conc between 85
& 125 mcg/mL. Max: 60 mg/kg/day.

Drug Depakote ER XR tab 250 mg 100's

Preparation (P3169.72/bottle, P31.70/tab)
Depakote ER XR tab 500 mg 100’s
(P5538.38/bottle, P55.38/tab)
Inj 5 mg/mL x 5's. (P1,122.91/ P224.58 per
vial)
 Schizophrenia
Drug DIAZEPAM (Valium)
Category Anxiolytic/ anticonvulsant benzodiazepine
MOA long-acting benzodiazepine w/ anticonvulsant,
anxiolytic, sedative, muscle relaxant and
amnestic properties. It increases neuronal
membrane permeability to Cl ions by binding
to stereospecific benzodiazepine receptors on
the postsynaptic GABA neuron w/in the CNS
and enhancing the GABA inhibitory effects
resulting in hyperpolarisation and stabilisation
Adverse Blured vision, urinary retention, paradoxical
Reaction reactions. Dependence, withdrawal symptoms
Drug Medicines to control seizures. Narcotics and
Interaction narcotic pain relievers. Muscle relaxants.
Sleeping medication. Antihistamines or allergy
medications. Monoamine oxidase .inhibitors,
tricyclic antidepressants, phenothiazines.
Therapeutic
Dose
Dosage Adults Relief of Severe anxiety and tension
Regimen Depending upon severity of symptoms - 2 mg
to 10 mg, two to four times daily.
Drug Tab 5mg x 100’s (P915)
Preparation 10mg x 100’s (P1,403)
Inj (amp) 10mg/2ml x 10’s (P898)
P224.58 per vial)
 Benign Prostatic Hyperplasia
Drug Tamsulosin HCL (Astellas)
Category Alpha-1 Adrenergic Blockers
MOA An alpha1 adrenoceptor blocking agent,
exhibits selectivity for alpha1 receptors in the
human prostate. At least 3 discrete alpha 1-
adrenoceptor subtypes have been identified:
aplha1A, alpha1B and alpha1D; their
distribution differs between organs and tissue.
Adverse Dizziness, abnormal ejaculation, headache,
Reaction postural hypotension and palpitations
Drug Increase plasma levels with cimetidine.
Interaction Decrease plasma levels with furosemide.
Increase elimination rate with diclofenac and
warfarin. Enhanced hypotensive effects with
other alpha adrenoreceptor antagonists.
Therapeutic 1 tab daily.
Dose
Dosage May be taken with or without food
Regimen
Drug Tablet
Preparation
 Benign Prostatic Hyperplasia
Drug Terazosin (Hytrin)
Category
MOA The reduction in symptoms and improvement
in urine flow rates following administration of
terazosin is related to relaxation of smooth
muscle produced by blockade of alpha-1
adrenoceptors in the bladder neck and
prostate.
Adverse Dizziness, drowsiness, nasal congestion,
Reaction nausea, peripheral edema, asthenia, postural
hypotension.

Drug Diuretics, alcohol, other antihypertensives.

Interaction
Therapeutic 1 mg at bedtime, increasing as needed; most
Dose patients require 10mg day.
Dosage May be taken with or without food
Regimen
Drug Tablet
Preparation
 Benign Prostatic Hyperplasia
Drug Doxazosin (Alfadil XL)
Category
MOA Selective blockade of alpha1 (post junctional)
subtype of adrenergic receptors.

Adverse Vertigo, asthenia, peripheral edema. Abdominal

Reaction pain, dyspepsia, nausea. Flu-like symptoms,
respiratory tract infection, UTI.
Drug PDE-5 inhibitors, ACE inhibitors, adrenergic
Interaction neuron blockers, alcohol, aldesleukin.

Therapeutic May recommended dose: 8mg once daily. Usual

Dose maintenance dose: 4mg daily.

Dosage May be taken with or without food

Regimen
Drug Tablet
Preparation
 Cushing Syndrome
Drug Ketoconazole (Nizoral)
Category Antifungal
MOA An imidazole derivative antimycotic agent,
inhibits several P450 enzymes and effectively
lowers cortisol in most patients with Cushing’s
disease when administered twice daily (600–
1200 mg/d).
Adverse Elevated hepatic transaminases, Gynecomstia,
Reaction Impotence, Gastrointestinal upset, Edema
Drug for the treatment of the following systemic
Interaction fungal infections in patients who have faled or
who are intolerant to other therapies:
blastomycosis, coccidoidomycosis,
histoplasmosis, chromomycois and
paracoccidioidomycosis.
Therapeutic Adult: starting dose: 200 mg TAB OD, if (+)
Dose insuffiency : increased to 400 mg TAB OD ;
Children: (2 yo) 3.3-6.6 mg/kg TAB OD
Dosage - usual duration of systemic therapy for
Regimen systemic infection is 6 mos. Treatment
should be continued until active fungal
infection subside.
Drug Tablet
Preparation
 Hirsutism & Satyriasis
Drug Cyproterone Acetate (althea)
Category Oral contraceptives
MOA Cyproterone is a progestogen with anti-
androgenic properties.
Adverse Nausea, vomiting, chloasma (melasma) & other
Reaction skin or hair changes, headache, water
retention, slight wt change, breast tenderness,
changes in libido. Menstrual irregularities eg
spotting, breakthrough bleeding & amenorrhea
Drug Hepatic microsomal enzyme inducers eg
Interaction barbiturates, St. John's wort, rifampin may
decrease contraceptive efficacy &/or increase
breakthrough bleeding. Anti-infective agents
may decrease contraceptive efficacy.
Troleandomycin may increase risk of cholestatic
jaundice. CYP3A4 inhibitors eg clarithromycin,
erythromycin, grapefruit juice, itraconazole,
ketoconazole, ritonavir may increase incidence
of adverse effects. Alcohol may reduce the
effectiveness of cyproterone acetate.
Therapeutic 1 tab starting on the 1st day of menses & for
Dose 21 days. Start new pack after 7 tab-free days.
Dosage May be taken with or without food.
Regimen
Drug Tablet
Preparation
 Hirsutism & Satyriasis
Drug Cyproterone Acetate (althea)
Category Oral contraceptives
MOA Cyproterone is a progestogen with anti-
androgenic properties.
Adverse Nausea, vomiting, chloasma (melasma) & other
Reaction skin or hair changes, headache, water
retention, slight wt change, breast tenderness,
changes in libido. Menstrual irregularities eg
spotting, breakthrough bleeding & amenorrhea
Drug Hepatic microsomal enzyme inducers eg
Interaction barbiturates, St. John's wort, rifampin may
decrease contraceptive efficacy &/or increase
breakthrough bleeding. Anti-infective agents
may decrease contraceptive efficacy.
Troleandomycin may increase risk of cholestatic
jaundice. CYP3A4 inhibitors eg clarithromycin,
erythromycin, grapefruit juice, itraconazole,
ketoconazole, ritonavir may increase incidence
of adverse effects. Alcohol may reduce the
effectiveness of cyproterone acetate.
Therapeutic 1 tab starting on the 1st day of menses & for
Dose 21 days. Start new pack after 7 tab-free days.
Dosage May be taken with or without food.
Regimen
Drug Tablet
Preparation